These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 1723893

  • 1. CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships.
    van Kammen DP, Peters J, Yao J, Neylan T, Beuger M, Pontius E, O'Connor DT.
    Schizophr Res; 1991 Dec; 6(1):31-9. PubMed ID: 1723893
    [Abstract] [Full Text] [Related]

  • 2. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP, Agren H, Yao JK, O'Connor DT, Gurklis J, Peters JL.
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [Abstract] [Full Text] [Related]

  • 3. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP, Peters J, van Kammen WB, Nugent A, Goetz KL, Yao J, Linnoila M.
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [Abstract] [Full Text] [Related]

  • 4. CSF chromogranin A-like immunoreactivity in schizophrenia: relationships with REM latency and slow wave sleep.
    van Kammen DP, O'Connor DT, Neylan TC, Mouton A, Gurklis JA, Gilbertson MW, Peters JL.
    Psychiatry Res; 1992 Apr; 42(1):53-63. PubMed ID: 1603881
    [Abstract] [Full Text] [Related]

  • 5. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
    van Kammen DP, Peters J, Yao J, van Kammen WB, Neylan T, Shaw D, Linnoila M.
    Arch Gen Psychiatry; 1990 Feb; 47(2):161-8. PubMed ID: 1689140
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA, Suddath RL, Bissette G, Nemeroff CB, Lowrimore P, Weinberger DR.
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [Abstract] [Full Text] [Related]

  • 9. Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients.
    Linnoila M, Ninan PT, Scheinin M, Waters RN, Chang WH, Bartko J, van Kammen DP.
    Arch Gen Psychiatry; 1983 Dec; 40(12):1290-4. PubMed ID: 6197036
    [Abstract] [Full Text] [Related]

  • 10. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
    van Kammen DP, Guidotti A, Kelley ME, Gurklis J, Guarneri P, Gilbertson MW, Yao JK, Peters J, Costa E.
    Biol Psychiatry; 1993 Oct 15; 34(8):515-22. PubMed ID: 8274578
    [Abstract] [Full Text] [Related]

  • 11. Clonidine treatment of schizophrenia: can we predict treatment response?
    van Kammen DP, Peters JL, van Kammen WB, Rosen J, Yao JK, McAdam D, Linnoila M.
    Psychiatry Res; 1989 Mar 15; 27(3):297-311. PubMed ID: 2469097
    [Abstract] [Full Text] [Related]

  • 12. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
    van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Peters JL.
    Arch Gen Psychiatry; 1995 Aug 15; 52(8):673-8. PubMed ID: 7543265
    [Abstract] [Full Text] [Related]

  • 13. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK, Colison J, Bartko JJ, Doran AR, Konicki PE, Potter WZ, Pickar D.
    Arch Gen Psychiatry; 1993 Aug 15; 50(8):606-14. PubMed ID: 7688209
    [Abstract] [Full Text] [Related]

  • 14. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients.
    Sedvall GC, Wode-Helgodt B.
    Arch Gen Psychiatry; 1980 Oct 15; 37(10):1113-6. PubMed ID: 6158928
    [Abstract] [Full Text] [Related]

  • 15. Atrophy limited to the third ventricle in chronic schizophrenic patients. Report of a controlled series.
    Boronow J, Pickar D, Ninan PT, Roy A, Hommer D, Linnoila M, Paul SM.
    Arch Gen Psychiatry; 1985 Mar 15; 42(3):266-71. PubMed ID: 2579616
    [Abstract] [Full Text] [Related]

  • 16. CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide.
    Roy A, Ninan P, Mazonson A, Pickar D, Van Kammen D, Linnoila M, Paul SM.
    Psychol Med; 1985 May 15; 15(2):335-40. PubMed ID: 2410941
    [Abstract] [Full Text] [Related]

  • 17. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ, Leahey W, Liddle J, King DJ.
    Schizophr Res; 1990 May 15; 3(4):261-7. PubMed ID: 1703780
    [Abstract] [Full Text] [Related]

  • 18. Melperone in the treatment of schizophrenia.
    Bjerkenstedt L.
    Acta Psychiatr Scand Suppl; 1989 May 15; 352():35-9. PubMed ID: 2479227
    [Abstract] [Full Text] [Related]

  • 19. Monoamine metabolite levels in cerebrospinal fluid and brain atrophy in lobotomized schizophrenic patients.
    Rimón R, Roos BE, Kampman R, Hyyppä S, Ranta P, Myllylä V.
    Ann Clin Res; 1979 Feb 15; 11(1):25-9. PubMed ID: 453776
    [Abstract] [Full Text] [Related]

  • 20. CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin).
    Miller C, Kirchmair R, Troger J, Saria A, Fleischhacker WW, Fischer-Colbrie R, Benzer A, Winkler H.
    Biol Psychiatry; 1996 Jun 01; 39(11):911-8. PubMed ID: 9162202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.